Multivalent Activation of GLP-1 and Sulfonylurea Receptors Modulates β-cell Second-messenger Signaling and Insulin Secretion
Overview
Physiology
Affiliations
Linking two pharmacophores that bind different cell surface receptors into a single molecule can enhance cell-targeting specificity to cells that express the complementary receptor pair. In this report, we developed and tested a synthetic multivalent ligand consisting of glucagon-like peptide-1 (GLP-1) linked to glibenclamide (Glb) (GLP-1/Glb) for signaling efficacy in β-cells. Expression of receptors for these ligands, as a combination, is relatively specific to the β-cell in the pancreas. The multivalent GLP-1/Glb increased both intracellular cAMP and Ca, although Ca responses were significantly depressed compared with the monomeric Glb. Moreover, GLP-1/Glb increased glucose-stimulated insulin secretion in a dose-dependent manner. However, unlike the combined monomers, GLP-1/Glb did not augment insulin secretion at nonstimulatory glucose concentrations in INS 832/13 β-cells or human islets of Langerhans. These data suggest that linking two binding elements, such as GLP-1 and Glb, into a single bivalent ligand can provide a unique functional agent targeted to β-cells.
Rajkovic J, Peric M, Stanisic J, Gostimirovic M, Novakovic R, Djokic V Pharmaceuticals (Basel). 2024; 17(7).
PMID: 39065708 PMC: 11280115. DOI: 10.3390/ph17070857.
Insulinoma-derived pseudo-islets for diabetes research.
Hart N, Weber C, Price N, Banuelos A, Schultz M, Huey B Am J Physiol Cell Physiol. 2021; 321(2):C247-C256.
PMID: 34106785 PMC: 8424674. DOI: 10.1152/ajpcell.00466.2020.